EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical and quality of life improvement after bilastine treatment among patients with autoimmune chronic spontaneous urticaria

My Tra Thi Nguyen, My Huyen Le, Minh Nguyet Vu, Katrine Baumann, Per Stahl Skov, Doanh Huu Le iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0326445 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von My Tra Thi Nguyen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hue University of Medicine and Pharmacy, Hue University, Vietnam. Hauptthemen laut MEDLINE: Quality of Life, Chronic Urticaria, Piperidines, Benzimidazoles. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aimed to evaluate the clinical effectiveness of bilastine in type IIb autoimmune CSU (type IIb aiCSU) patients over an 8-week period, as well as to identify factors predicting treatment response.

Method

34 type IIb aiCSU patients with positive basophil histamine release assays (BHRA) and positive Autologous Serum Skin Test (ASST) tests, from the Vietnam National Dermatology and Venereology Hospital, were included. Patients began treatment with the standard dose of bilastine, with the dose increased every two weeks for those who did not achieve adequate response. The Urticaria Control Test (UCT), Weekly Urticaria Activity Score (UAS7), and the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) were used.

Results

Significant improvements in all measures were observed, with 82.4% of patients achieving complete response by week 8. Of these, 47.1% responded to the standard dose, while 14.7% did not respond even at the maximum (x4) dose. UAS7 average scores decreased from a baseline mean of 28.9 to 2.9, indicating substantial reduction in disease activity. UCT scores improved from 47.1% of patients having poor disease control (UCT < 12) after week 2 to 85.3% achieving good control (UCT ≥ 12) by week 8. QoL also significantly improved, with CU-Q2oL scores dropping from 44.9 at baseline to 25.3 at week 8. Basopenia, high baseline UAS7 score and a history of autoimmune disease were associated with poorer treatment responses, while normal/high IgE levels were linked to better outcomes.

Conclusion

The findings suggest that bilastine is highly effective in controlling aiCSU symptoms and improving QoL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeChronic UrticariaPiperidinesBenzimidazolesAutoimmune DiseasesUrticariaHumansMaleFemaleAdultMiddle AgedTreatment OutcomeYoung AdultSurveys and Questionnaires

Substanzen

PiperidinesbilastineBenzimidazoles

Autor:innen und Institutionen

  • Hue University of Medicine and Pharmacy, Hue University, Vietnam.
  • Hanoi Medical University, Hanoi, Vietnam.
  • National Dermatology and Venereology Hospital, Hanoi, Vietnam.
  • RefLab ApS, Hvidovre, Denmark.

ORCID-Profile: Doanh Huu Le

Zitieren

APA

Nguyen, M. T. T., Le, M. H., Vu, M. N., Baumann, K., Skov, P. S., & Le, D. H. (2025). Clinical and quality of life improvement after bilastine treatment among patients with autoimmune chronic spontaneous urticaria. PLOS One. https://doi.org/10.1371/journal.pone.0326445

Vancouver

Nguyen MTT, Le MH, Vu MN, Baumann K, Skov PS, Le DH. Clinical and quality of life improvement after bilastine treatment among patients with autoimmune chronic spontaneous urticaria. PLOS One. 2025. doi:10.1371/journal.pone.0326445

BibTeX
@article{Nguyen2025,
  author = {Nguyen, My Tra Thi and Le, My Huyen and Vu, Minh Nguyet and Baumann, Katrine and Skov, Per Stahl and Le, Doanh Huu},
  title = {Clinical and quality of life improvement after bilastine treatment among patients with autoimmune chronic spontaneous urticaria},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0326445}
}
Kostenlos starten →